Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Next Previous
Search
Trial Profile

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Busulfan (Primary) ; Ciclosporin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mesna (Primary) ; Methotrexate (Primary) ; Ruxolitinib (Primary) ; Thiotepa (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jul 2024 Status changed from recruiting to discontinued.
    • 18 Oct 2022 New trial record
    • 17 Oct 2022 According to ClinicalTrials.gov record, protocol has been amended as the study design changed from Single Group Assignment to Parallel Assignment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top